SCHEMBL5316539

SCHEMBL5316539

Cc1cc(Cl)ccc1Cn1nc(CCC(=O)O)c2ccc(OC(F)(F)F)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.44
SLC22A12 Q96S37 4/20 0.44
PPARG P37231 8/20 0.42
PPARA Q07869 4/20 0.41
KCNH2 Q12809 2/20 0.41
CYP2C9 P11712 1/20 0.41
EGFR P00533 1/20 0.41
CHRM4 P08173 1/20 0.41
ADRB1 P08588 1/20 0.41
ADRA2A P08913 1/20 0.41
ALOX5 P09917 1/20 0.41
ADRB3 P13945 1/20 0.41
DRD2 P14416 1/20 0.41
ADRA2B P18089 1/20 0.41
CHRM3 P20309 1/20 0.41
TACR2 P21452 1/20 0.41
DRD1 P21728 1/20 0.41
TBXA2R P21731 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5319585 0.95 KMO (0.44) KMOSLC22A12PPARGPPARAKCNH2
SCHEMBL5318197 0.91 PTGDR2 (0.49) KMOSLC22A12PPARGPPARAKCNH2
SCHEMBL5319646 0.91 PPARG (0.49) KMOSLC22A12PPARGCYP2C9PTGDR2
SCHEMBL5316549 0.90 SLC22A12 (0.42) KMOSLC22A12PPARGPPARAKCNH2
SCHEMBL5318343 0.89 PPARG (0.38) KMOPPARGPPARAKCNH2CYP2C9
SCHEMBL5271055 0.87 PPARG (0.37) PPARGPPARAKCNH2CYP2C9EGFR
SCHEMBL5273572 0.87 F2RL3 (0.40) PPARGPPARAKCNH2CYP2C9EGFR
SCHEMBL5316023 0.86 PPARG (0.46) KMOSLC22A12PPARGKCNH2CYP2C9
SCHEMBL5338753 0.86 PPARG (0.36) PPARGPPARAKCNH2CYP2C9EGFR
SCHEMBL5346874 0.85 PPARG (0.36) PPARGPPARAKCNH2CYP2C9EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2502624-A1 Lonidamine analogues and their use in male contraception and cancer treatment THE UNIVERSITY OF KANSAS (US) 2012-09-26 EP claimed
EP-1786424-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT The University of Kansas (US) 2007-05-23 EP claimed
WO-2006023704-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT UNIVERSITY OF KANSAS (US) 2006-03-02 WO claimed